Hasco Medical, Inc. Reports Record 2014 Results

ADDISON, TX--(Marketwired - March 30, 2015) -

2014 Audited Financial and Operational Highlights

• Revenues up 24.8% to $91 million over YTD 2013
• Service and other revenue up 26.3% to $16.2 million vs YTD 2013
• Gross profit increased 29.8% to $23.3 million as compared to YTD 2013
• Net income increased 160% to a record $2.1 million vs. YTD 2013
• EBITDA increased 73.9% to a record $5.2 million vs. YTD 2013

2014 Financial Summary
Record revenues of $91.0 million as compared to revenues of $72.9 million for the year ended December 31, 2013, an increase of $18.1 million or approximately 24.8%.

Service and other revenues of $16.2 million as compared to revenues of $12.8 million for the year ended December 31, 2013, an increase of $3.4 million or 26.3%.

Overall gross profit increased to $23.3 million or 25.6% for the year ended December 31, 2014 from $18.0 million or 24.7% for the year ended December 31, 2013, an increase of $5.3 million or 29.8%.

Net income was recorded at a record high $2.1 million for the year ended December 31, 2014 compared to net income of $0. 8 million for the year ended December 31, 2013 an increase of 160% or $1.3 million.

EBITDA for the year ended December 31,2014 was $5,194,216 an increase of $2,207,305 or 73.9% as compared to $2,986,911 for the year ended December 31, 2013.

Management Commentary
"Our team continues its excellent execution by driving sales in our wheelchair vehicle sales and service business. These results are a testament to the increasing success of our brands and the successful delivery of our growth plan by our management team," said Hal Compton, CEO of HASCO Medical. "This year we are anxious to launch the new Ford Explorer based BraunAbility MXV Sport Utility wheelchair accessible SUV and the Chevrolet Suburban based Mobility SVM SUV. These vehicles represent a paradigm shift in the wheelchair accessible vehicle market and Ride-Away® and Mobility Freedom are positioned with trained Mobility Consultants to deliver on customer expectations. I see these vehicles as increasing the accessible market."

"Our new Commercial Sales Department has already seen success in 2015 with a series of wins in our Boston, Mid-Atlantic and South Florida markets. The new Ford Transit and Dodge ProMaster vehicles are reinvigorating a market that is looking to replace aging Ford E Series vehicles."

"We are eager to grand open our Parkville, Maryland location on April 17th and 18th, and our new Miami location is currently under construction and we expect it to be complete by Q2 2015."

"This year represents a number of unique opportunities with vehicle introductions, new Commercial Sales division and store openings. These drivers will enhance our sales and bottom line by better meeting the needs of our customers."

About HASCO Medical, Inc.
HASCO Medical is a leading provider of wheelchair accessible vehicles, parts, and service that dramatically improve the quality of living of its customers. Founded in 2008, HASCO Medical is headquartered in Addison, TX. The company operates 20 locations in 11 states from Maine to Florida. The company's mobility brands include Ride-Away (www.Ride-Away.com), Mobility Freedom (www.MobilityFreedom.com) and Wheelchair Vans of America (www.WCVans.com). To learn more, go to www.HASCOMed.com.

Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify those so-called "forward looking statements" by words such as "may," "will," "should," "expects," "plans," "targets," "believes," "anticipates," "estimates," "predicts," "potential," or "continue" or the negative of those words and other comparable words. These forward looking statements are subject to risks and uncertainties, product tests, commercialization risks, availability of financing and results of financing efforts that could cause actual results to differ materially from historical results or those anticipated. Further information regarding these and other risks is described from time to time in the Company's filings with the SEC, which are available on its website at: http://www.sec.gov. We assume no obligation to update or alter our forward-looking statements made in this release or in any periodic report filed by us under the Securities Exchange Act of 1934 or any other document, whether as a result of new information, future events or otherwise, except as otherwise required by applicable federal securities laws.

EBITDA is not a measure of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to operating income or net income as an indicator of our operating performance or to net cash provided by operating activities as a measure of our liquidity.

                                                                            
                                                                            
                    Hasco Medical, Inc. and Subsidiaries                    
                   Consolidated Statements of Operations                    
                      For the Years Ended December 31,                      
                                                                            
                                                 2014             2013      
                                           ---------------  --------------- 
                                                                            
Product sales                              $    73,498,940  $    58,800,359 
Rental revenue                                   1,307,053        1,276,154 
Service and other                               16,213,515       12,837,102 
                                           ---------------  --------------- 
  Total net revenues                            91,019,508       72,913,615 
                                           ---------------  --------------- 
                                                                            
                                           ---------------  --------------- 
Cost of sales                                   67,684,020       54,935,899 
                                           ---------------  --------------- 
                                                                            
Gross profit                                    23,335,488       17,977,716 
                                                                            
Operating expenses:                                                         
  Selling and marketing                          4,169,497        3,350,612 
  General and administrative                    14,228,076       11,905,466 
  Amortization and depreciation                    964,330        1,053,808 
                                           ---------------  --------------- 
    Total operating expenses                    19,361,903       16,309,886 
                                           ---------------  --------------- 
                                                                            
Income from operations                           3,973,585        1,667,830 
                                                                            
Other income (expense):                                                     
  Other income                                       6,525          487,311 
  Interest expense                              (1,103,517)      (1,068,971)
                                           ---------------  --------------- 
    Total other income (expense)                (1,096,992)        (581,660)
                                           ---------------  --------------- 
                                                                            
Income from continuing operations before                                    
 income taxes                                    2,876,593        1,086,170 
                                                                            
Provision for income taxes                       1,045,966           62,578 
                                           ---------------  --------------- 
Income from continued operations                 1,830,627        1,023,592 
Gain(Loss) from discontinued operations            249,776         (222,038)
                                           ---------------  --------------- 
Net income                                 $     2,080,403  $       801,554 
                                           ===============  =============== 
                                                                            
Earnings per share:                                                         
  Basic and dilutive - continued                                            
   operations                              $          0.00  $          0.00 
                                           ===============  =============== 
  Basic and dilutive - discontinued                                         
   operations                              $          0.00  $          0.00 
                                           ===============  =============== 
                                                                            
Weighted average shares outstanding                                         
  Basic and dilutive                         1,000,518,665      989,545,590 
                                           ===============  ===============